Vtesse

Vtesse is a rare disease therapeutic drug developer and the first spin-off company of Cyphan Development. The company focuses on clinical research of VTS-270 for the treatment of Niemann-Pick type C disease, as well as the discovery and development of preclinical new drugs for nasopharyngeal carcinoma and other lysosomal storage disorders. Vtesse is led by an experienced management team that has been involved in the development of more than 20 approved drugs and vaccines.